论文部分内容阅读
There is not only a need for scientific data regarding the risk of recurrence of breast cancer by starting hormone replacement therapy (HRT) but also regarding the patients’ needs for HRT. Objectives: To examine the severity of climacteric complaints in breast cancer patients and to examine if they are willing to take HRT. Methods: In November 2003, a questionnaire was sent to 469 breast cancer survivors. The survey examined on a scale base the severity of climacteric complaints and the patient’s opinion on starting HRT. Results: More than 76% of the patients complained that they experience or had experienced hot flushes or night sweating. More than half (53% ) of this group found the inconvenience severe to extreme, affecting the patient’s quality of life. A majority (80.5% ) patients who had already taken HRT, found that it improved their quality of life substantially. When the results of observational studies were explained regarding HRT in breast cancer survivors, a majority said they would take or would consider taking HRT (57.9% ). Conclusion: While physicians are more reserved in prescribing HRT in breast cancer survivors, a combination of severe symptomatic climacteric complaints and the willingness of the patient to be treated should at least result in a “ consideration” of prescribing HRT.
There is not only a need for scientific data regarding the risk of recurrence of breast cancer by starting hormone replacement therapy (HRT) but also regarding the patient ’needs for HRT. Objectives: To examine the severity of climacteric complaints in breast cancer patients and to Methods: In November 2003, a questionnaire was sent to 469 breast cancer survivors. The survey examined on a scale base of severity of climacteric complaints and the patient’s opinion on starting HRT. Results: More than 76 % of the patients complained that they experience or had experienced hot flushes or night sweating. More than half (53%) of this group found the inconvenience severe to extreme, affecting the patient’s quality of life. A majority (80.5%) patients who had already the results of observational studies were explained regarding HRT in breast cancer survivors, a majority said t hey would take or would not consider taking HRT (57.9%). Conclusion: While physicians are more reserved in prescribing HRT in breast cancer survivors, a combination of severe symptomatic climacteric complaints and the willingness of the patient to be treated should at least result in a “Consideration” of prescribing HRT.